BJH - 2018, issue Abstract Book BHS, february 2018
M. Hofmans MD, PhD, dr. A. Delie MD, K. Vandepoele PhD, N. Van Roy PhD, J. Van der Meulen , J. Philippé MD, PhD, I. Moors MD
BJH - 2018, issue Abstract Book BHS, february 2018
I. Moors MD, T. Kerre MD, PhD, B. Denys MD, M. Hofmans MD, PhD, K. Vandepoele PhD
BJH - 2018, issue Abstract Book BHS, february 2018
C. De Vriendt , S. Kennes MD, M. Hofmans MD, PhD, P. Vlummens MD
BJH - volume 8, issue 2, march 2017
A-S. De Koninck PharmD, C. Dhooge MD, PhD, B. Denys MD, K. Vandepoele PhD, N. Van Roy PhD, M. Hofmans MD, PhD, J. Philippé MD, PhD
We describe a case of a four-year-old boy diagnosed with an Early T-cell Precursor Lymphoblastic Leukaemia. This type of leukaemia is recognised as a high-risk subgroup characterised by very early arrest in T-cell differentiation. Early T-cell Precursor Lymphoblastic Leukaemia cases have characteristic gene expression profiles, increased genomic instability and a distinct immature immunophenotype (CD1a–, CD8–, CD5+dim and positivity for at least one marker of stem cell or myeloid lineage). This type of leukaemia is associated with poor prognosis and a poor response to intensive chemotherapy, though this finding is still debated. Our patient displayed an inferior response to induction therapy. The main purpose of this report is to make Belgian physicians aware of this entity and its controversial prognostic significance.
(BELG J HEMATOL 2017;8(2):75–9)
Read moreBJH - volume 8, issue Abstract Book BHS, february 2017
dr. A. Delie MD, M. Hofmans MD, PhD, P. Vlummens MD
BJH - volume 6, issue Abstract Book BHS, january 2015
M. Hofmans MD, PhD, P. Meeus MD, E. Bailleul
Top
